Myeloproliferative Neoplasms | Specialty

Dr. Rampal on Investigational Agents in MPNs

February 22nd 2020

Raajit K. Rampal, MD, PhD, discusses investigational agents in myeloproliferative neoplasms.

Dr. Kuykendall on Toxicity Profiles of Ruxolitinib and Fedratinib in Myelofibrosis

February 21st 2020

Andrew T. Kuykendall, MD, discusses the toxicity profiles of ruxolitinib and fedratinib in myelofibrosis.

Dr. Kremyanskaya on Responses With CPI-0610 in Patients With Myelofibrosis

February 21st 2020

Marina Kremyanskaya, MD, PhD, discusses responses with CPI-0610 in patients with myelofibrosis.

Dr. Garcia on the Role of Navitoclax in Myelofibrosis

February 21st 2020

Jacqueline S. Garcia, MD,discusses how navitoclax differs from other agents in primary or secondary myelofibrosis.

Expert Highlights Luspatercept Benefit as Treatment of Anemia in Myelofibrosis

February 21st 2020

Aaron Gerds, MD, discusses data presented at the 2019 ASH Annual Meeting highlighting luspatercept as a treatment of anemia in patients with myelofibrosis.

Panobinostat Combo Shows Early Promise in Myelofibrosis and Polycythemia Vera

February 21st 2020

The combination of panobinostat and ruxolitinib demonstrated efficacy and a tolerable safety profile as a treatment for patients with primary myelofibrosis and post-polycythemia vera–related myelofibrosis and post essential thrombocythemia–related myelofibrosis.

FDA Grants Priority Review to Cedazuridine/Decitabine for MDS and CMML

February 14th 2020

The FDA has granted a priority review designation to a new drug application for cedazuridine plus decitabine for the treatment of adult patients with previously untreated intermediate- and high-risk myelodysplastic syndromes or chronic myelomonocytic leukemia.

Dr. Bose on Treating Progression in Patients With Myelofibrosis

February 14th 2020

Prithviraj Bose, MD, discusses treatment for patients with progressive myelofibrosis.

Dr. Mesa on New Trials and Agents in the Myelofibrosis Pipeline

February 12th 2020

Ruben A. Mesa, MD, discusses new trials and agents in the pipeline in myelofibrosis.

Dr. Snyder on the Utility of Transplant in MPNs

February 11th 2020

David S. Snyder, MD, discusses the utility of transplant in myeloproliferative neoplasms.

FDA Grants Breakthrough Designation to APR-246/Azacitidine Combo in TP53-Mutant MDS

January 31st 2020

The FDA has granted a breakthrough therapy designation to the combination of APR-246 and azacitidine for the treatment of patients with myelodysplastic syndromes with a susceptible TP53 mutation.

Ruxolitinib Combo Elicits Clinical Activity in Polycythemia Vera and Myelofibrosis

January 30th 2020

The combination of ruxolitinib (Jakafi) plus low-dose pegylated interferon-a2 demonstrated an improvement in peripheral blood cell counts bone marrow cellularity and fibrosis, and symptom burden with acceptable toxicity in patients with polycythemia vera or proliferative myelofibrosis.

Navitoclax Activity Confirmed in Ruxolitinib-Resistant Myelofibrosis

January 30th 2020

Jacqueline S. Garcia, MD, discusses the design and findings of a phase II trial of navitoclax and details next steps for the BCL-XL/BCL-2 inhibitor.

Mesa Shares Insight on Fedratinib Benefit in Myelofibrosis Subgroup

January 30th 2020

Ruben Mesa, MD, discusses findings from a pooled analysis of fedratinib at full dose in patients with myelofibrosis who had low platelet counts.

Direct Oral Anticoagulants Show Prophylactic Potential in MPN-Induced Thrombosis

January 30th 2020

Srikanth Nagalla, MD, discusses the management of cancer-related thrombosis in myeloproliferative neoplasms, as well as updates in immune thrombocytopenic purpura.

Emerging Therapies in Essential Thrombocytopenia

January 30th 2020

Treating Patients With Essential Thrombocytopenia

January 30th 2020

Treatment of Myelofibrosis: Emerging Therapies

January 30th 2020

Combining Ruxolitinib With Other Agents

January 30th 2020

The Role of Fedratinib in Myelofibrosis

January 30th 2020